Analyst Price Targets — BDTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:54 am | Kelsey Goodwin | Piper Sandler | $8.00 | $2.67 | TheFly | Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler |
| October 15, 2025 8:31 pm | Laura Prendergast | Stifel Nicolaus | $8.00 | $4.14 | TheFly | Black Diamond Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:15 pm | Brad Canino | Guggenheim | $8.00 | $2.88 | TheFly | Black Diamond Therapeutics initiated with a Buy at Guggenheim |
| July 31, 2024 8:18 am | Laura Prendergast | Raymond James | $20.00 | $5.91 | TheFly | Black Diamond Therapeutics initiated with an Outperform at Raymond James |
| June 3, 2024 8:52 am | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX) |
| May 16, 2024 6:12 am | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | TheFly | Black Diamond price target lowered to $11 from $12 at H.C. Wainwright |
| April 8, 2024 7:07 am | Robert Driscoll | Wedbush | $16.00 | $5.06 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $16 at Wedbush |
| March 18, 2024 6:38 am | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $12 at H.C. Wainwright |
Latest News for BDTX
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BDTX.
U.S. House Trading
No House trades found for BDTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.